PBM
PHAT icon

Propel Bio Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Propel Bio Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
1,050,358
+209,086
+25% +$2.39M 5.96% 4
2026
Q1 		$9.35M Buy
841,272
+100,354
+14% +$1.27M 5.9% 3
2025
Q4 		$12.3M Buy
740,918
+187,991
+34% +$2.68M 10.49% 3
2025
Q3 		$6.51M Sell
552,927
-370,000
-40% -$3.82M 6.51% 6
2025
Q2 		$8.85M Sell
922,927
-212,000
-19% -$1.17M 10.74% 4
2025
Q1 		$7.12M Buy
1,134,927
+145,000
+15% +$880K 8.27% 4
2024
Q4 		$8.04M Buy
989,927
+120,000
+14% +$1.49M 7.98% 6
2024
Q3 		$15.7M Hold
869,927
– – 9.12% 3
2024
Q2 		$8.96M Hold
869,927
– – 5.81% 6
2024
Q1 		$9.24M Buy
869,927
+426,880
+96% +$3.63M 5.38% 6
2023
Q4 		$4.05M Buy
+443,047
New +$3.82M 3.35% 8

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Propel Bio Management's PHAT Position: Q2 2026 in Review

Propel Bio Management increased its Phathom Pharmaceuticals (PHAT) stake by 25% in Q2 2026, buying an estimated $2.39M and bringing the position to 1,050,358 shares worth $11.4M. The position accounts for 5.96% of the portfolio, ranked #4.

Propel Bio Management first reported a position in PHAT in Q4 2023 and has held it in 11 quarters since. The position peaked at $15.7M in Q3 2024. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Propel Bio Management held 1,050,358 shares of Phathom Pharmaceuticals worth $11.4M as of Q2 2026.
  • Propel Bio Management bought 209,086 Phathom Pharmaceuticals shares in Q2 2026, an estimated $2.39M.
  • Phathom Pharmaceuticals made up 5.96% of Propel Bio Management's portfolio in Q2 2026, its #4 holding.
  • Propel Bio Management first reported a position in Phathom Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Propel Bio Management's Phathom Pharmaceuticals position peaked at $15.7M in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.